claudia.gentile

Postdoc in the Kadoch lab at Dana-Farber Cancer Institute. Interested in epigenetic gene regulation and cell signalling in development and disease.

[Dana-Farber News @DanaFarberNews]

A study in @Cancer_Cell, led by Matthew Oser, MD, PhD (@Oser_Lab) & Cigall Kadoch, PhD (@CKadoch) at @danafarber identify SWI/SNF inhibitors as a potential targeted treatment for POU2F3-positive small cell lung cancer, accounting for 12% of cases.
Study ▶️ https://t.co/reoHu0eeFa

[claudia.gentile @claudiagentile_]

@ajinkyapatil00 @kadochlab @DanaFarber @DanaFarberNews @CellCellPress Congrats @ajinkyapatil00 this is so well deserved! A masterpiece 🙌🏻

[Dana-Farber News @DanaFarberNews]

New study by Cigall Kadoch, PhD (@CKadoch) @DanaFarber reveals the sequence-specific contributions of intrinsically disordered proteins known as IDRs, which are implicated in cancer. @Cell
https://t.co/foHXycudcZ

[Dana-Farber News @DanaFarberNews]

Featured in @TheScientistLLC, research in lung cancer cell lines co-led by @DanaFarber's Cigall Kadoch, PhD ( @CKadoch), found that chromatin remodeling underlies one type of osimertinib resistance. https://t.co/s9zD3ZDV0V

[claudia.gentile @claudiagentile_]

@JF_CoteLab Merci 😁

[claudia.gentile @claudiagentile_]

I am honoured to have received the 2023 Next Generation of Scientists Award from the #CancerResearchSociety to support my transition to an independent academic position! #postdoc #CanadianCancerResearch

[Société de recherche sur le cancer @SRC_CRS]

🏆🌟 Congratulations to the 5 recipients of our 2023 Next Generation of Scientists Award! 🔬 👩‍🔬👨‍🔬
✨Together, let’s invest in the future of research to outsmart cancer! 💪
👉To learn more: https://t.co/ePAAUYStuy

#CancerResearchSociety #CancerResearch #OutsmartCancer

[claudia.gentile @claudiagentile_]

@ChiaraGamberi Thank you!!

[Société de recherche sur le cancer @SRC_CRS]

🏆🌟 Félicitations aux 5 récipiendaires de notre Bourse pour la relève scientifique 2023 ! 🔬 👩‍🔬👨‍🔬
✨Ensemble, investissons dans l'avenir de la recherche pour déjouer le cancer ! 💪
👉Pour en savoir plus : https://t.co/WMgDGaStGg
#SocietedeRecherchesurleCancer #RechercheCancer

[Cell @CellCellPress]

Today Cell, Cancer Cell and Cell Reports Medicine are pleased to publish the 1st wave of Pan-#Cancer multiomics papers looking at over 1000 patients across 10 #tumor types from @theNCI Clinical Proteomic Tumor Analysis Consortium #CPTAC (1/n) @Cancer_Cell @CellRepMed #openaccess

[Yale Cancer Center @YaleCancer]

"This study has revealed a new vulnerability of a subset of lung #adenocarcinomas that have become resistant to standard-of-care targeted therapies,” said Dr. Katerina Politi @politikaterina.
https://t.co/d62iELaf9O
@SmilowCancer @YaleMed @YNHH @yalepathology @Cancer_Cell

[Cancer Cell @Cancer_Cell]

Online Now: Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer https://t.co/9vEIvTo1nK

[claudia.gentile @claudiagentile_]

@FranExpositoR @CR_AACR @politikaterina @YaleMed @YaleCancer @CIMA_unav Congrats @FranExpositoR on this huge accomplishment!

[claudia.gentile @claudiagentile_]

@FranExpositoR @fdemiguelsdp @DanaFarber @kadochlab @DanaFarberNews Thank you so so much @FranExpositoR!!

[claudia.gentile @claudiagentile_]

Excited to share that my postdoc work is now published in Cancer Cell! This work, co-led by @fdemiguelsdp and myself, reveals that mSWI/SNF complexes promote TKI resistance in #EGFR-mutant lung cancer. @DanaFarber @kadochlab @DanaFarberNews
https://t.co/3QnzLWFBB3
Tweetorial ⬇️

[claudia.gentile @claudiagentile_]

Huge thank you to all the amazing scientists who contributed to this collaborative effort to merge the worlds of #epigenetics and #cellsignaling. Especially my mentor @CKadoch!

[claudia.gentile @claudiagentile_]

Finally, the combination treatment of osimertinib and a SMARCA4/2 inhibitor, FHD-286, slows tumour progression in a PDX model, emphasizing the potential utility of mSWI/SNF inhibitors to treat TKI-resistant lung cancers. 6/n